Document is current

Any future updates will be listed below

Cost-effectiveness analysis of bortezomib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (VR-CAP) in patients with previously untreated mantle cell lymphoma

Crossref DOI link: https://doi.org/10.1186/s12885-016-2633-2

Published Online: 2016-08-04

Published Print: 2016-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark